Follistatin 344: Dosage, Benefits, Side Effects and Legal Status
The short answer
Follistatin 344 (FS344) is the 344 amino acid form of follistatin, a human protein that blocks myostatin and activin A. We found no FDA-approved follistatin product and no established dose: the only human data come from gene therapy trials, where a viral vector carried the FS344 gene into leg muscle, not from injecting a vial. In two small trials with no placebo group, four of six Becker muscular dystrophy patients walked 29 to 125 m further in six minutes and four of six sporadic inclusion body myositis patients gained 58 to 153 m. We found no trial of follistatin protein injected from a research vial, so the vials sold under the name have no human dosing data behind them.
This page separates what has been tested in people from what is sold in vials. Every figure below comes from a registry record, a paper, a protein database or a regulator page opened on 31 October 2026, or from the Bureau's own Vendor Watch data. The full list is under Sources.
What follistatin 344 is, and why "follistatin peptide" is a loose label
Follistatin is a secreted glycoprotein, not a short peptide. The human FST gene makes two forms by alternative splicing. The long form is a 344 amino acid precursor with a calculated mass of about 38 kilodaltons (UniProt P19883). Its mature chain, residues 30 to 344, is the 315 residue form called FS315. The shorter splice form is FS288.
The number is a label for the gene construct, not a grade or a potency. The Becker muscular dystrophy trial team chose FS344 "to avoid potential binding to off target sites", and a review by the same group says FS315, the form FS344 becomes, binds activin with about a tenfold lower affinity than FS288.
For scale, BPC-157 has 15 residues and a molecular weight of 1419.54 g/mol (HHS policy document, Appendix B). The follistatin precursor is about 27 times heavier.
How follistatin works
Follistatin is a binding protein. It does not switch a receptor on. It captures ligands outside cells and blocks their type II receptor binding site (UniProt). Its targets include activin A, myostatin (GDF-8), GDF-11 and bone morphogenetic proteins.
Myostatin limits muscle size. Belgian Blue and Piedmontese cattle carry myostatin gene mutations and are double muscled (McPherron and Lee, 1997), and mice lacking myostatin have about twice the muscle mass of normal mice (Lee, 2007). Follistatin also binds activin A, which is why it can suppress pituitary FSH release (UniProt) and why the Nationwide Children's gene therapy team said it called for caution (Al-Zaidy 2015).
Follistatin 344 benefits: what the evidence shows
Every benefit claim traces back to the studies in this table. Only the last three rows involve people, and in the two that report results the follistatin gene was injected into leg muscle with a viral vector.
| Evidence | What was done | What was reported | Source |
|---|---|---|---|
| Mice | Follistatin made in skeletal muscle by a transgene | "Dramatic increases in muscle mass comparable to those seen in myostatin knockout mice" | Lee and McPherron, PNAS 2001 |
| Mice, no myostatin | Same transgene in myostatin-null mice | About four times the muscle mass of normal mice, against about twice for myostatin-null mice alone | Lee, PLoS One 2007 |
| Macaques | AAV1-FS344 injected into the quadriceps | "Pronounced and durable increases in muscle size and strength"; no abnormal changes in key organs | Kota et al., Sci Transl Med 2009 |
| Becker muscular dystrophy, 6 patients | AAV1-FS344 into both quadriceps | 4 of 6 walked 29 to 125 m further in 6 minutes; 2 did not improve | Mendell et al., Mol Ther 2015 |
| Sporadic inclusion body myositis, 6 patients | AAV1-FS344, 6E11 vg/kg, both quadriceps | Median change +56.0 m a year, against -25.8 m a year in 8 untreated matched patients; 4 of 6 gained 58 to 153 m | Mendell et al., Mol Ther 2017 |
| Healthy adults, 43 people | Follistatin plasmid (Minicircle) | DXA body composition scans planned; no results posted | ClinicalTrials.gov NCT06411366 |
Science Translational Medicine published an erratum to the macaque paper on 5 August 2026. We have not read what it corrects.
What this does not show. Both human trials were small single-group studies with no placebo group. The sporadic inclusion body myositis comparison used eight untreated patients matched for age, sex and baseline measures, and every participant followed an exercise regimen. The authors also note that more advanced disease "poses challenges". None of this tells a healthy lifter what a vial will do.
Related drugs show why added muscle and added function are different endpoints. In a single-dose study of 48 healthy postmenopausal women, the 3 mg/kg group of ACE-031 showed increases of 3.3% in total body lean mass and 5.1% in thigh muscle volume at day 29. The myostatin antibody MYO-029 showed no improvement in exploratory strength or function endpoints in 116 muscular dystrophy patients (the study was not powered for efficacy), and bimagrumab gave no meaningful functional benefit in sporadic inclusion body myositis.
Follistatin gene therapy: the human trials
Follistatin gene therapy is investigational. These are the registered human studies we found on ClinicalTrials.gov on 31 October 2026, searching follistatin, FS344, FST344 and follistatin 344. Doses are vector genomes per kilogram (vg/kg): a count of virus particles, not micrograms of protein.
| Registry ID | Who | What was given | People | Dates and status |
|---|---|---|---|---|
| NCT01519349 | Becker muscular dystrophy and sporadic inclusion body myositis (Nationwide Children's Hospital) | AAV1 vector carrying FS344 into the quadriceps: 2E11 vg/kg (one leg), 3E11 or 6E11 vg/kg per quadriceps | 15 enrolled | Jan 2012 to Oct 2017, completed |
| NCT02354781 | Duchenne muscular dystrophy (Nationwide Children's Hospital) | AAV1-FS344 into gluteal, quadriceps and tibialis anterior muscles: 2.4E12 vg/kg in total, 1.2E12 per limb | 3 enrolled, 6 planned | Jan 2015 to Nov 2017, completed, results posted |
| NCT06411366 | Healthy adults (Minicircle) | Injectable plasmid carrying the human FST344 gene; dose not given in the registry summary | 43 | Aug 2022 to Aug 2023, completed, no results posted |
| NCT07285629 | Healthy adults (Minicircle) | Klotho and follistatin plasmid | 14 | Dec 2025 to Apr 2026, completed, no results posted |
| NCT07443826 | Adults aged 35 to 75 with age-related muscle decline (Unlimited Biotechnology) | AAV9 follistatin, 5E10 or 1E11 vg/kg, alone or with a VEGF plasmid; rapamycin for about two months to blunt the immune response to the vector | 12 planned | From June 2026, recruiting, estimated completion June 2028 |
- Becker trial, 6 patients. Three patients received 3E11 vg/kg per leg: two improved on the six minute walk test by 58 m and 125 m and one showed no change. Three received 6E11 vg/kg per leg: two improved by 108 m and 29 m and one showed no improvement. The authors report "No adverse effects were encountered". Muscle biopsies showed less fibrosis and muscle fibre hypertrophy, especially at the high dose (Mendell 2015).
- Sporadic inclusion body myositis trial, 6 patients. Treated patients changed by a median +56.0 m a year against -25.8 m a year in eight untreated matched patients (p = 0.01). Four of six gained 58 to 153 m and two gained 5 to 23 m. Treatment effects included decreased fibrosis and improved regeneration (Mendell 2017).
- Duchenne trial, 3 patients. The registry results list no dose limiting toxicity and one serious event, a head injury from a fall.
- Immune suppression. Before injection, Becker trial participants took prednisone for a month to try to prevent an immune response to the AAV capsid (Al-Zaidy 2015 review). This is a supervised medical procedure, not a vial.
Closest stocked compound in this pathway: ACE-031 at Pantheon
Follistatin 344 is not a standing catalogue item at any of the 13 vendors on the Bureau's scorecard, and that absence is informative rather than inconvenient. ACE-031 is the compound in the same signalling family that does have a human trial record, including the adverse events that ended its development, and Pantheon lists it with a batch certificate of analysis. Research use only.
Check ACE-031 at Pantheon Compare all vendorsWhy a gene therapy result does not transfer to a vial
The trials delivered the follistatin gene into the muscle being measured and checked for the transgene in muscle biopsies 180 days later (registry record). A vial is a different intervention: the protein is injected instead of being made in place, in an amount no trial has tested.
We found no registered trial that injects follistatin protein. Searches on ClinicalTrials.gov returned gene therapy studies, viral vector or plasmid, and studies that only measure follistatin levels. So there is no measured dose, duration of effect or safety record for a vial.
Identity is a separate problem. Vendor Watch, the Bureau's price tracker, covers 17 vendors and found no follistatin product in its 31 October 2026 read, so there is no vendor certificate of analysis for us to review. How to spot a fake peptide vendor covers what a certificate of analysis can and cannot tell you.
Follistatin 344 dosage: what is and is not documented
There is no established dose of follistatin 344. No trial we found gave follistatin as an injected protein, so no study has measured a protein dose, an effect or a safety margin.
| Where a "dose" comes from | Unit | Usable as a vial dose? |
|---|---|---|
| AAV gene therapy trials (Becker, sporadic inclusion body myositis, Duchenne) | vg/kg: 3E11 or 6E11 per leg in the Becker trial, 2.4E12 in total in the Duchenne trial | No. It counts virus particles, not protein. |
| Plasmid gene therapy studies | Not given in the registry summaries we read | No. |
| Forum and vendor schedules | Micrograms a day, varying by source | No source we could open. Not repeated here. |
An earlier version of this page listed community dose figures. We removed them on 31 October 2026 because we could not tie any of them to a trial, a label or a regulator. If you see a follistatin 344 dose quoted elsewhere, ask what it was derived from.
Follistatin 344 side effects and safety
Nobody has measured the side effects of injected follistatin 344 in people. What exists is safety reporting from the gene therapy trials and from drugs that act on the same pathway.
- Becker gene therapy trial: the authors report "No adverse effects were encountered" in six patients.
- Duchenne gene therapy trial (3 patients, registry results): no dose limiting toxicity and one serious event, a head injury from a fall. Pain in all three patients and bruising in two were the most common other events listed.
- Immune response to the vector: Becker trial participants took prednisone for a month before injection, and the 2026 AAV9 trial gives rapamycin for about two months for the same purpose.
- Hormonal axis: follistatin binds activin A and can suppress pituitary FSH release (UniProt). The Nationwide Children's gene therapy team named this as a reason for caution (Al-Zaidy 2015).
- Same pathway, other drugs: ACE-031, an activin receptor fusion protein, was stopped in a Duchenne trial over nosebleeds and dilated small skin vessels (epistaxis and telangiectasias). The myostatin antibody MYO-029 was associated with cutaneous hypersensitivity at 10 and 30 mg/kg.
None of these results carries over to a vial of unknown content. They are why the Bureau treats follistatin 344 as a research question and not a product recommendation.
If the goal is muscle growth
If you came here for muscle growth rather than for this molecule, the IGF-1 LR3 guide covers another route people take for muscle growth, with its dosing and drawbacks.
IGF-1 LR3 at AminoClub. Stocked as a standing item with batch testing published, which is the minimum bar for a compound people run for weeks. Research use only.
Check IGF-1 LR3 at AminoClubMuscle growth peptides sets out the category, the muscle growth stack page covers how the pieces combine, and MK-677 is the oral option for anyone who would rather not inject.
Is follistatin 344 legal?
HHS policy, 30 October 2026. HHS published an interim enforcement discretion policy for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Follistatin is not one of them. The policy covers State-licensed pharmacies, Federal facilities and licensed physicians under stated conditions, and the Federal Register notice says the draft policy "does not establish any rights for any person and is not binding on HHS or the public" (91 FR 68526). Our news story covers the six peptides, the ten conditions and what the text leaves out.
FDA approval. We found no FDA-approved follistatin product. Searches of the openFDA drug label and Drugs@FDA endpoints for follistatin on 31 October 2026 returned no matches.
FDA warning letter, 2020. In a letter dated 1 April 2020, FDA told a compounding pharmacy that drug products it compounded using follistatin, among other substances, were not eligible for the section 503A exemptions, because the substances were not the subject of a USP or NF monograph, not a component of an FDA-approved human drug and not on the 503A bulks list. The pharmacy had told FDA in October 2018 that it had stopped selling follistatin.
Follistatin 344 sold as a research chemical is a separate case, and what the research use only label does and does not do is covered in the legal status guide. This page is not legal advice and cannot tell you whether buying a vial is lawful where you live.
Follistatin 344 price and sourcing
Vendor Watch, the Bureau's price tracker, covers 17 vendors. Its 31 October 2026 read has no follistatin 344 listing, so we quote no price, and the Bureau does not score any vendor on follistatin. The Pantheon review explains how the scorecard treats the vendor in the box above.
If the underlying goal is a growth oriented protocol rather than this specific molecule, a CJC-1295 and ipamorelin blend is a common alternative that the Bureau covers.
CJC-1295 and ipamorelin, no DAC, at AminoClub. The standard secretagogue pairing, sold as a pre blended vial with batch documentation. Research use only.
Check the blend at AminoClubKey takeaways
- Follistatin 344 is the 344 residue precursor of a human protein, mature form FS315, that blocks myostatin and activin A. We found no approved follistatin product.
- Every human result comes from gene therapy, a viral vector or plasmid carrying the gene, not from injected protein.
- The Becker and sporadic inclusion body myositis trials had six patients each, no placebo group, and four of six walked further in each.
- There is no established vial dose. Gene therapy doses are in vg/kg and cannot be converted to micrograms.
- Safety of injected follistatin has not been measured in people. Drugs on the same pathway were stopped (ACE-031) or did not show functional gains (MYO-029, bimagrumab).
- Follistatin is not among the six peptides in the HHS interim policy of 30 October 2026, and we found no approved follistatin product.
- Vendor Watch lists no follistatin product at 17 vendors, so we quote no price.
Frequently Asked Questions
What is follistatin 344?
Follistatin 344 (FS344) is the 344 amino acid precursor of human follistatin, a secreted protein that binds and blocks activin A, myostatin and related growth factors. Its mature chain, residues 30 to 344, is the 315 residue form called FS315. The name FS344 became known through gene therapy trials in which a viral vector carried the FS344 gene into muscle, not through injections of the protein.
What is the follistatin 344 dosage?
There is no established dose. No trial we found gave follistatin as an injected protein. The only doses with a source are gene therapy vector doses, such as 3E11 and 6E11 vector genomes per kilogram (vg/kg) per leg in the Becker muscular dystrophy trial, which count virus particles and cannot be converted into a vial dose. Microgram schedules on forums and vendor pages have no trial behind them, so the Bureau does not repeat them.
What are the benefits of follistatin 344?
In mice and macaques, follistatin made from a transgene or a delivered gene increased muscle mass, and in macaques muscle strength too. In people the evidence is two small gene therapy trials in muscle disease: four of six Becker patients walked 29 to 125 m further in six minutes, and sporadic inclusion body myositis patients gained a median 56.0 m a year while eight untreated matched patients lost 25.8 m. Neither trial had a placebo group, and none tested a vial in healthy people.
What are the side effects of follistatin 344?
Side effects of injected follistatin 344 have not been studied in people. The Becker gene therapy trial reported no adverse effects in six patients, and the registry results for three patients with Duchenne list no dose limiting toxicity and one serious event, a head injury from a fall. Follistatin can suppress pituitary FSH release, which the Nationwide Children's gene therapy team flagged as a reason for caution, and ACE-031, a drug acting on the same pathway, was stopped in a Duchenne trial over nosebleeds and dilated skin vessels.
Is follistatin 344 legal?
We found no FDA-approved follistatin product. On 30 October 2026 HHS published an interim enforcement discretion policy for 503A compounding of six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and follistatin is not one of them. In a 2020 warning letter FDA said pharmacy products compounded with follistatin were not eligible for the section 503A exemptions. This page cannot tell you whether buying a research vial is lawful where you live.
Is follistatin gene therapy available?
Not as an approved treatment. Follistatin gene therapy is investigational: Nationwide Children's Hospital ran AAV1-FS344 trials in Becker muscular dystrophy, sporadic inclusion body myositis and Duchenne muscular dystrophy, a company called Minicircle registered plasmid studies in healthy adults with no results posted, and a trial of AAV9 follistatin in adults aged 35 to 75 started in June 2026 and is recruiting.
Does follistatin 344 build muscle in healthy people?
That has not been shown. The human trials enrolled patients with muscle disease and used gene therapy. The one registered study in healthy adults, a follistatin plasmid given to 43 people, lists DXA body composition scans but has posted no results. Mouse and macaque studies used genes expressed in muscle, not vial injections.
Is follistatin 344 a peptide?
Not in the usual sense. Follistatin is a glycoprotein: the 344 residue precursor has a calculated mass of about 38 kilodaltons, roughly 27 times the 1419.54 g/mol of BPC-157, which has 15 residues. The shorter splice form is FS288, and the Becker trial team chose FS344 partly to avoid potential off target binding.
Sources
- ClinicalTrials.gov, NCT01519349, rAAV1.CMV.huFollistatin344 in Becker muscular dystrophy and sporadic inclusion body myositis (Nationwide Children's Hospital): clinicaltrials.gov/study/NCT01519349. Checked 31 October 2026.
- ClinicalTrials.gov, NCT02354781, rAAV1.CMV.huFollistatin344 in Duchenne muscular dystrophy, with posted results: clinicaltrials.gov/study/NCT02354781. Checked 31 October 2026.
- ClinicalTrials.gov, NCT06411366, injectable follistatin plasmid in healthy subjects (Minicircle): clinicaltrials.gov/study/NCT06411366. Checked 31 October 2026.
- ClinicalTrials.gov, NCT07285629, klotho and follistatin plasmid in healthy adults (Minicircle): clinicaltrials.gov/study/NCT07285629. Checked 31 October 2026.
- ClinicalTrials.gov, NCT07443826, AAV9 follistatin with or without a VEGF plasmid (Unlimited Biotechnology): clinicaltrials.gov/study/NCT07443826. Checked 31 October 2026.
- Mendell JR et al., A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy, Molecular Therapy 2015 (PubMed 25322757): pubmed.ncbi.nlm.nih.gov/25322757/. Checked 31 October 2026.
- Mendell JR et al., Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes, Molecular Therapy 2017 (PubMed 28279643): pubmed.ncbi.nlm.nih.gov/28279643/. Checked 31 October 2026.
- Al-Zaidy SA et al., Follistatin gene therapy improves ambulation in Becker muscular dystrophy, Journal of Neuromuscular Diseases 2015 (PubMed 27858738): pubmed.ncbi.nlm.nih.gov/27858738/. Checked 31 October 2026.
- Kota J et al., Follistatin gene delivery enhances muscle growth and strength in nonhuman primates, Science Translational Medicine 2009 (PubMed 20368179); erratum published 5 August 2026, not reviewed: pubmed.ncbi.nlm.nih.gov/20368179/. Checked 31 October 2026.
- Lee SJ and McPherron AC, Regulation of myostatin activity and muscle growth, PNAS 2001 (PubMed 11459935): pubmed.ncbi.nlm.nih.gov/11459935/. Checked 31 October 2026.
- Lee SJ, Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways, PLoS One 2007 (PubMed 17726519): pubmed.ncbi.nlm.nih.gov/17726519/. Checked 31 October 2026.
- McPherron AC and Lee SJ, Double muscling in cattle due to mutations in the myostatin gene, PNAS 1997 (PubMed 9356471): pubmed.ncbi.nlm.nih.gov/9356471/. Checked 31 October 2026.
- UniProt P19883 (FST_HUMAN), human follistatin: sequence length, mature chain, isoforms FS315 and FS288, function: uniprot.org/uniprotkb/P19883/entry. Checked 31 October 2026.
- Attie KM et al., A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers, Muscle and Nerve 2013 (PubMed 23169607): pubmed.ncbi.nlm.nih.gov/23169607/. Checked 31 October 2026.
- Campbell C et al., Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy, Muscle and Nerve 2017 (PubMed 27462804): pubmed.ncbi.nlm.nih.gov/27462804/. Checked 31 October 2026.
- Wagner KR et al., A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy, Annals of Neurology 2008 (PubMed 18335515): pubmed.ncbi.nlm.nih.gov/18335515/. Checked 31 October 2026.
- Amato AA et al., Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT, Neurology 2021 (PubMed 33597289): pubmed.ncbi.nlm.nih.gov/33597289/. Checked 31 October 2026.
- Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice 2026-22192, 91 FR 68526, published 30 October 2026: federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discre. Checked 31 October 2026.
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (peptide list) and Appendix B (BPC-157 molecular weight and sequence): hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-po. Checked 31 October 2026.
- FDA, warning letter to Tailor Made Compounding LLC, case 594743, 1 April 2020: fda.gov/inspections-compliance-enforcement-and-criminal-investigations. Checked 31 October 2026.
- openFDA drug label and Drugs@FDA endpoints, queried for follistatin (api.fda.gov/drug/label.json and api.fda.gov/drug/drugsfda.json): no matches. Checked 31 October 2026.
- Peptide Bureau Vendor Watch, list prices at 17 vendors, read 31 October 2026: no follistatin listing.
Medical disclaimer
This article is for educational and informational purposes only and is not medical advice. We found no approved follistatin product, and material sold under the name follistatin 344 is supplied for laboratory research only. Nothing here is a recommendation to obtain or administer any compound. Doses quoted from trials are viral vector doses, not doses of follistatin protein, and are not a guide to use. Consult a qualified clinician before making any decision about your health.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes